Laurent Chardonnet Net Worth

The estimated Net Worth of Laurent Chardonnet is at least $3.19 Million dollars as of 23 May 2023. Mr Chardonnet owns over 5,000 units of Axcella Health Inc stock worth over $193,116 and over the last 19 years he sold AXLA stock worth over $2,425,188. In addition, he makes $576,064 as Consultant at Axcella Health Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr Chardonnet AXLA stock SEC Form 4 insiders trading

Mr has made over 18 trades of the Axcella Health Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of AXLA stock worth $27,500 on 23 May 2023.

The largest trade he's ever made was exercising 113,776 units of Axcella Health Inc stock on 30 March 2015 worth over $1,889,819. On average, Mr trades about 13,210 units every 139 days since 2006. As of 23 May 2023 he still owns at least 42,165 units of Axcella Health Inc stock.

You can see the complete history of Mr Chardonnet stock trades at the bottom of the page.

Mr. Laurent Chardonnet biography

Laurent Chardonnet is the Consultant at Axcella Health Inc.

What is the salary of Mr Chardonnet?

As the Consultant of Axcella Health Inc, the total compensation of Mr Chardonnet at Axcella Health Inc is $576,064. There are 5 executives at Axcella Health Inc getting paid more, with Shreeram Aradhye having the highest compensation of $3,911,720.

How old is Mr Chardonnet?

Mr Chardonnet is 56, he's been the Consultant of Axcella Health Inc since . There are 7 older and 9 younger executives at Axcella Health Inc. The oldest executive at Axcella Health Inc is Catherine Sohn, 67, who is the Independent Director.

What's Mr Chardonnet's mailing address?

Laurent's mailing address filed with the SEC is C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805.

Insiders trading at Axcella Health Inc

Over the last 6 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa..., and Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.

What does Axcella Health Inc do?

axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.

Complete history of Mr Chardonnet stock trades at Incyte, Axcella Health Inc, and Prelude Therapeutics Inc

Axcella Health Inc executives and stock owners

Axcella Health Inc executives and other stock owners filed with the SEC include:

• Shreeram Aradhye,
  Executive Vice President, Chief Development Officer
• Manu Chakravarthy,
  Senior Vice President, Chief Medical Officer
• William Hinshaw,
  President, Chief Executive Officer, Director
• David Epstein,
  Chairman of the Board
• William R. Hinshaw Jr.,
  Pres, CEO & Director
• Laurent Chardonnet,
  Consultant
• William Baird,
  Independent Director
• Catherine Sohn,
  Independent Director
• Gary Pisano,
  Independent Director
• Gregory Behar,
  Independent Director
• Cristina Rondinone,
  Independent Director
• Stephen Hoge,
  Independent Director
• Stephen Mitchener,
  Senior Vice President, Chief Business Officer
• Paul Fehlner,
  Senior Vice President, Chief Intellectual Property Officer
• Heidy King-Jones,
  Senior Vice President of Legal, General Counsel
• Tony Tramontin,
  Senior Vice President of Research and Development , Chief Scientific Officer
• Laurent Chardonnet,
  Chief Financial Officer, Senior Vice President
• Karim Azer Ph.D.,
  VP of Systems Biology & Discovery
• Dr. Margaret Koziel M.D.,
  Sr. VP & Chief Medical Officer
• Dr. Alison D. Schecter M.D.,
  Pres of R&D
• Dr. Larry Bell,
  Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP
• Virginia R. Dean,
  Sr. VP & Chief People Officer
• Dr. Paul Fehlner J.D., Ph.D.,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Jason Fredette,
  VP of Investor Relations & Corp. Communications
• Health Science Us Holdings,...,
  
• Michael Rosenblatt,
  Director
• David A Berry,
  Director
• Ventures Fund Iv General Pa...,
  
• Paul J Sekhri,
  Director
• Ventures Fund Iv General Pa...,
  
• Des Produits Nestle S.A.Nes...,
  
• Alison D. Schecter,
  President - Research & Dev.
• Virginia R Dean,
  SVP, Chief People Officer
• Margaret Koziel,
  Chief Medical Officer
• Ventures Fund Iv General Pa...,
  
• Robert Crane,
  Chief Financial Officer
• Torben Straight Nissen,
  Director
• Robert L. Rosiello,
  Director